1. Home
  2. Directory
  3. Missouri
  4. Florissant
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1720032600

DR. LUCIAS DANIEL MEYER O.D.
Prescription History 1720032600
Optometrist in Florissant, MO

NPI Status: Active since May 22, 2006

Contact Information

230 N LINDBERGH BLVD
FLORISSANT, MO
ZIP 63031
Phone: (314) 921-9377
Fax: (314) 830-2940

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. LUCIAS DANIEL MEYER O.D., an active Optometrist specialist practicing in Florissant, MO. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 157 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 99 claims alone.

Medication Index

Brimonidine Tartrate-Timolol

Generic Formulation: Brimonidine Tartrate/TimololSpecialty: Optometry
Provider Metrics Summary
Total Claims 14
30-Day Fills 15.5
Days Supply 410
MO State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills34.8
Peer Average Days Supply978
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,241.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$160.12

State Avg Cost Per Claim

$277.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.

Therapeutic Applications

This combination medication is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This product contains brimonidine and timolol. These medications are used together when 1 drug is not controlling the pressure inside the eye. Brimonidine works by allowing better fluid drainage from within the eye and also by decreasing the amount of fluid formed in the eye. It belongs to a class of drugs known as alpha agonists. Timolol is thought to work by decreasing the amount of fluid formed in the eye. Timolol belongs to a class of drugs known as beta blockers. This medication is not recommended for use in children less than 2 years old due to an increased risk of serious side effects. Ask the doctor or pharmacist for more details.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 28.9
Days Supply 865
MO State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills144.4
Peer Average Days Supply4,318
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.4% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $449.93 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.61

State Avg Cost Per Claim

$31.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 99
30-Day Fills 205.2
Days Supply 5,910
MO State Average Benchmarks
Peer Average Claims127.0
Peer Average 30-Day Fills225.3
Peer Average Days Supply6,436
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,367.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.92

State Avg Cost Per Claim

$23.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 19
30-Day Fills 33.0
Days Supply 990
MO State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills60.1
Peer Average Days Supply1,761
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $23,137.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,217.78

State Avg Cost Per Claim

$1,017.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 12
30-Day Fills 18.2
Days Supply 546
MO State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills126.3
Peer Average Days Supply3,712
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.0% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $152.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.74

State Avg Cost Per Claim

$19.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. LUCIAS DANIEL MEYER O.D. provides transparency into local medical care patterns within Florissant, MO.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.